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CYP19 regulationThe enzyme aromatase, encoded by the CYP19A1 gene, catalyzes the production of estrogens and inhibition of
aromatase has therefore becomeone of the key strategies in breast cancer treatment.Wehave studied the effects
of the vitamin D analog EB1089 on aromatase gene expression and enzyme activity in breast cancer cells. We
found that EB1089 was able to decrease the gene expression and enzyme activity as well as inhibit
aromatase-dependent cell growth. Furthermore, a low dose of EB1089 combined with low doses of clinically
used aromatase inhibitors such as anastrozole, letrozole and exemestane were able to effectively inhibit
aromatase-dependent growth of breast cancer cells. The molecular mechanism for this effect of EB1089 on the
aromatase gene expression was investigated and we found that it is mediated by the vitamin D receptor
(VDR), vitamin D receptor interacting repressor (VDIR) and Williams syndrome transcription factor (WSTF).
ChIP and Re-ChIP assays revealed that EB1089 mediates dissociation of WSTF from the CYP19A1 promoter and
thereby decreases the gene expression. Regulation of aromatase viaWSTF has not been reported previously. Fur-
thermore, gene silencing ofWSTF results in decreased gene expression of CYP19A1 and aromatase activity, show-
ing that WSTF is an interesting drug target for development of new anti-cancer drugs. In summary, we report
that the vitamin D analog EB1089 is able to decrease the gene expression and enzyme activity of aromatase
via a novel regulatory pathway for aromatase and suggest that EB1089may be a new treatment option for estro-
gen dependent breast cancer.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
About 80% of all breast cancers are classiﬁed as estrogen receptor
positive, and the majority of these tumors rely on estrogens to prolifer-
ate. The enzyme aromatase, encoded by theCYP19A1 gene, catalyzes the
conversion of androgens to estrogens and inhibition of aromatase has
therefore become one of the key strategies in breast cancer treatment.
Treatment of breast cancer patients with the anti-estrogen tamoxifen
has been ﬁrst line endocrine therapy for more than 30 years, but today
treatment with a third generation aromatase inhibitor like letrozole,
anastrozole or exemestane is the recommendedﬁrst line endocrine ther-
apy for most postmenopausal women.
The existing aromatase inhibitors have drawbacks; the treatment
is associated with adverse effects due to inhibition of aromatase in
bone cells and a large group of patients develop resistance to the aro-
matase inhibitors [1]. To overcome some of these drawbacks, drug
candidates have been sought that would alter estrogenic signallingl rights reserved.and estrogen production in a tissue-selective manner [2–6]. The se-
lective estrogen receptor modulators (SERM) raloxifen and tamoxifen
are examples of such tissue-selective anti-estrogens. However, tissue-
selective aromatase inhibitors have not yet been developed. The ex-
pression of CYP19A1 is regulated in a tissue-selective manner, using
different promoters distributed over a 93 kilobase regulatory region
upstream of the CYP19A1 gene [3–5]. The promoters that drive
CYP19A1 gene expression may differ between tissues, but also be-
tween normal tissue and cancer tissue. It has, for example, been
reported that normal breast cells use CYP19A1 promoter I.4, while
CYP19A1 gene expression is driven by promoters I.3 and II in breast
cancer cells [3,7]. This use of tissue-selective CYP19A1 promoters
has been proposed as a possible strategy for development of selective
aromatase modulators (SAM) [4,6].
We have studied a new principle of tissue-selective inhibition of
aromatase and the molecular mechanisms for regulation of aromatase
gene expression. The hormonally active form of vitamin D has recent-
ly been reported to be a tissue-selective aromatase modulator [8,9]
that inhibits aromatase activity in breast cancer cells, while the activ-
ity is increased or unaltered in cells derived from bone, prostate and
adrenal cortex [8,9]. Furthermore, 1α,25-dihydroxyvitamin D3 has
been shown to increase aromatase activity in placental cells [10,11],
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that vitamin D receptor null mutant mice have a decreased aromatase
activity in the ovary, testis and epididymis. Based on these data, it
has been proposed that 1α,25-dihydroxyvitamin D3 acts as a selective
aromatase modulator and therefore is an interesting substance for fur-
ther research in the ﬁeld of breast cancer prevention and treatment
[8,9]. However, clinical use of high-dose vitamin D treatment would
lead to adverse effects e.g. hypercalcemia. Therefore, vitamin D analogs
with less pronounced hypercalcemic effect have been synthesized. It
has been reported that one of these vitamin D analogs, EB1089
((1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(1R,2E,4E)-6-Ethyl-6-hydroxy-
1-methyl-2,4-octadien-1-yl]-octahydro-7α-methyl-4H-inden-4-ylidene]
ethylidene]-4-methylene-1,3-cyclohexanediol), decreases the prolifera-
tion of breast cancer cells, especially anti-estrogen resistant breast cancer
cells [15,16]. Furthermore, different animal studies have shown that
EB1089 is able to reduce mammary tumor progression in vivo in rats
[17–19] and mice [20–24] and it has also been reported that treatment
with EB1089 increased the survival time and inhibited bone metastases
in mice [20]. In rat, the effect of EB1089 was found to be superior to the
effect of 1α,25-dihydroxyvitamin D3 [17]. EB1089 has undergone clinical
phase I and II trials and was found to be a well tolerated compound [25].
However, the clinical trials have shown mixed results of EB1089 as an
anti-cancer agent in humans. No objective response was observed in a
trial with patients with inoperable pancreatic cancer [26], while more
promising datawas obtained in a studywith patientswith inoperable he-
patocellular carcinoma [25]. In a very small study, with patients with ad-
vanced forms of breast or colorectal cancers, no clear-cut anti-tumor
effect was observed, but the author states that this might be due to the
fact that the patients included in the study had advanced forms of carci-
nomas and had been heavily treated with other drugs prior to inclusion
in the study [27].
We have studied the effect of EB1089 on aromatase expression and
function in breast cancer cells. Our aimhas been to investigate if EB1089
can inhibit aromatase catalyzed formation of estrogens and thereby
have potential as a tissue-selective aromatase modulator. Our hypothe-
sis is that treatment with tissue-selective aromatase inhibitors would
have less adverse effects than the existing aromatase inhibitors. Fur-
thermore, we have investigated the molecular mechanisms for the
effects of EB1089 on the aromatase gene expression and we report
a novel mechanism for vitamin D receptor-mediated regulation of
CYP19A1 gene transcription.
2. Materials and methods
2.1. Chemicals
1α,25-Dihydroxyvitamin D3 and EB1089 were purchased from
Tocris Biosciences,Minneapolis, MN. Other chemicals were of analytical
grade and purchased from various commercially available sources.
2.2. Cell cultures
Human breast cancer MCF-7 cells have been adapted to grow in
a standard growth medium consisting of DMEM/F12 (Gibco) supple-
mented with 1% fetal bovine serum (Gibco), 2.5 mM glutamax (Nunc,
Roskilde, Denmark) and 6 ng/ml insulin (Novo Nordisk, Copenhagen,
Denmark). The cells were cultured as monolayers in a humidiﬁed envi-
ronment at 37 °Cwith 5% CO2. Growthmediumwas renewed every sec-
ond or third day, and the cellswere subcultivated by trypsination once a
week.
2.3. Quantitative RT-PCR
Expression of mRNA for CYP19A1 was measured using real-time
RT-PCR. Cells were lysated and RNA was isolated using PureLink
Micro-to-Midi Total RNA Puriﬁcation System (Invitrogen) and reversetranscribed to cDNA by SuperScript III First-Strand Synthesis SuperMix
(Invitrogen). The real-time PCR analysiswas performedwith LightCycler
FastStart DNA Master SYBR Green I (Roche) using a LightCycler
2.0 (Roche). All experiments were conducted in accordance to the
manufacturer's recommendations. Human TATA box binding protein
(TBP) was used as endogenous control. All real-time RT-PCR data were
normalized to the endogenous control. The relative mRNA expression
was calculated with the 2ΔΔCt method and expressed as fold change
compared to the untreated group. Primers and programs for CYP19A1
were as previously described by Díaz-Cruz et al. [28].
2.4. Cell growth assays
In cell growth experiments, 1.5×104 cells were seeded per well in
24-well plates. Growthmediumwas exchangedwithmedium containing
hormones at the speciﬁed concentrations 2 days after seeding (day 0).
Medium was renewed day 3 and day 5. At day 6, the multi-well plates
were incubated with a crystal violet solution (0.5% crystal violet w/v in
25% methanol v/v) for 10 min. Exceeding dye was washed off in tap
water, the dye was re-dissolved (0.1 M sodium citrate-dihydrate in 50%
ethanol) and the optical density (OD) for each well was measured at
570 nm. Each treatment was made in quadruplicate and growth is
expressed relative to vehicle treated cell growth.
2.5. Assay of aromatase-dependent cell growth
To assay the aromatase-dependent cell growth of MCF-7 cells we
adopted the methodology described by Sonne-Hansen and Lykkesfeldt
[29] where breast cancer cells depend on aromatase activity to pro-
liferate. Brieﬂy described, MCF-7 cells were seeded in normal growth
media (see above). At day 3, the medium was changed to DMEM/F12
(Gibco) supplemented with 10% newborn calf serum (Gibco), 2.5 mM
glutamax (Nunc, Roskilde, Denmark) and 6 ng/ml insulin (Novo Nordisk,
Copenhagen, Denmark). Newborn calf serum contains very low levels of
estrogens, andMCF-7 cells grow very slowly under these culturing condi-
tions. Cell growth can be stimulated by addition of 100 nM testosterone,
which will be converted to estradiol by aromatase and thereby stimulate
cell growth. The cells were treated with ethanol (control) or different
concentrations of EB1089 or 1α,25-dihydroxyvitamin D3 and cell growth
was assayed using crystal violet staining as described above.
2.6. Effects of combined treatment with EB1089 and clinically used
aromatase inhibitors
In order to evaluate the combined effect of EB1089 and clinically
used aromatase inhibitors, we cultured MCF-7 cells in a manner
where they rely on aromatase activity to proliferate (see above for
further details). The cell growth was stimulated by addition of 100 nM
testosterone and the cells were then treated with either clinically used
aromatase inhibitor alone, or in combination with EB1089 or 1α,25-
dihydroxyvitamin D3. Cell growthwas assayed using crystal violet stain-
ing as described above.
2.7. Aromatase enzyme activity assay
To determine the aromatase enzyme activity, the aromatase-
catalyzed conversion of testosterone to estradiol was measured. Cells
were cultured as described above and treated with different concentra-
tions of EB1089 for 72 h. Following the treatment, cell culture medium
was changed to DMEM/F12 (Gibco) supplemented with 10% newborn
calf serum (Gibco), 2.5 mM glutamax (Nunc, Roskilde, Denmark) and
6 ng/ml insulin (Novo Nordisk, Copenhagen, Denmark) and the aroma-
tase substrate testosterone (100 nM) was added. These culturing con-
ditions stimulate aromatase activity [19]. After 48 h incubation, the
cell culture medium was collected and the estradiol concentration
was measured using enzyme-linked immunosorbent assay (ELISA).
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GmbH, Germany. The analyses were performed in accordance with
the manufacturer's recommendations.
2.8. Chromatin immunoprecipitation assay (ChIP) and Re-ChIP
Chromatin immunoprecipitation assay was performed using EZ-
Magna ChIP kit (Millipore) in accordance with the manufacturer's rec-
ommendations. MCF-7 cells were cultured as described above and
treatedwith 0.1 μMof EB1089 dissolved in ethanol for 1 h or 24 h. Con-
trol cells were treated with the same amount of ethanol. The cells were
then cross-linked by adding formaldehyde and the chromatin was
subjected to immunoprecipitation using antibodies against VDR, WSTF
or VDIR (Santa Cruz Biotechnology). Antibodies against acetyl-histone
H3 and normal mouse IgG, included in the EZ-Magna ChIP kit, were
used as positive and negative control. Input control, negative control
and positive control were analyzed using quantitative PCR using
primers speciﬁc for human GAPDH promoter, included in the EZ-
Magna ChIP kit. Immunoprecipitated DNA was used for quantitative
PCR ampliﬁcation using primers speciﬁc for different parts of the
CYP19A1 promoter, previously reported to be putative vitamin D re-
sponse elements [9]. The previously reported nVDREs are located be-
tween −373 and −358 bp (distal nVDRE) and −299 and −284 bp
(proximal nVDRE), compared to the transcriptional start site. The prim-
er sequences were as described by Krishnan et al. [9]. The results are
expressed as fold change of DNAamount compared to the ethanol treat-
ed samples.
To study simultaneous binding of receptor and cofactors to the
different promoter regions, we adopted the methodology of Re-ChIP.
The Re-ChIP assaywas performed using EZ-Magna ChIP kit (Millipore)
in accordance with the manufacturer's recommendations for Re-ChIP.
Sonicated cells were subjected to immunoprecipitation with anti-
bodies directed against VDIR. The chromatin was then eluted and
the samples were subjected to a second immunoprecipitation using
antibodies against VDR, WSTF or VDIR. Immunoprecipitated DNA
from the Re-ChIP assay was used for quantitative PCR ampliﬁcation
using the primers described above.2.9. Gene silencing
To silence the gene expression of WSTF, MCF-7 cells were trans-
fected with siRNA targeting WSTF. SMART pool siRNA targeting WSTF
(M-006901) andnon-targeting control pool (D-001810)were purchased
from Dharmacon. Transfection was done using Cell Line Nucleofector kit
V and Nucleofector II (Amaxa) according to manufacturer's instructions.
To investigate the effect of silenced WSTF expression on cell growth,
transfected cells were seeded in 6-well plates with normal growth
medium. After 48 h, the mediumwas changed to experimental medium
containing very low levels of estrogens. The cells were then treated with
either testosterone or vehicle alone (ethanol). The experimentalmedium
was changed after 2 days. Onday 6, cell growthwas assayedusing crystal
violet assay as described above. To study the effect of silenced WSTF
expression on CYP19A1 gene expression, transfected cells were cultured
in experimental medium containing very low levels of estrogens with
an addition of testosterone for 4 days and the cells were then subjected
to RNA extraction and quantitative real-time RT-PCR with primers for
CYP19A1 as described in Section 2.3. The effectiveness of the gene
silencing was conﬁrmed with western blot analysis. Cells transfected
with siRNA targeting WSTF or scrambled siRNA were harvested by
washing the cells with ice-cold PBS and lysing in RIPA buffer. Determina-
tion of protein concentration was performed using the Bio-Rad protein
assay. Proteins were separated by SDS-PAGE and blotted onto PVDF
membranes which were blocked for 2 h with 5% dry skim milk, 0.2%
FCS, and 0.2% Tween-20 in TBS. Immunostaining was performed over
night with primary antibodies: Hsp-70 (Neo Markers) and WSTF(Santa Cruz Biotechnologies). Blots were washed four times with
TBS/0.1% Tween-20 followed by incubation for 1 h with species-speciﬁc
peroxidase-conjugated secondary antibodies (DAKO). Detection was
done using ECLplus reagent (GE Healthcare) and a Fujiﬁlm image reader
(LAS1000).
2.10. Statistical analysis
Analysis of statistical signiﬁcance was performed using Student's
t-test. P-valuesb0.05 were considered statistically signiﬁcant.
3. Results
3.1. CYP19A1 gene expression is down regulated following treatment
with EB1089
To study if the vitamin D analog EB1089 is able to alter the expres-
sion of the CYP19A1 gene, which encodes for aromatase, we cultured
breast cancer MCF-7 cells under standard conditions. The cells were
treated for 24 h with ethanol (control) or EB1089 in the concentra-
tion 10 nM or 100 nM. Following treatment, the cells were harvested
and RNA extracted and used in a real-time RT-PCR assay to measure
the expression of the CYP19A1 gene.
We found that treatment with both EB1089 and the hormonally
active form of vitamin D, 1α,25-dihydroxyvitamin D3, decreased the
gene expression of CYP19A1 signiﬁcantly compared to ethanol treated
cells (Fig. 1A). The effect of EB1089 was most pronounced in the sam-
ples that had been treated with 100 nM, where the CYP19A1 gene ex-
pression was decreased by 55% compared to control.
3.2. EB1089 suppresses aromatase-dependent growth of breast cancer
cells
To study the effect of EB1089 on aromatase-dependent cell
growth we adopted the methodology described by Sonne-Hansen
and Lykkesfeldt [29]. In this method, MCF-7 cells are cultured in medi-
um containing low levels of estrogens and supplemented with testos-
terone. Under these culture conditions, the cell growth is dependent
on the cells ability to convert testosterone to estrogens via aromatase,
mimicking the situation in estrogen-sensitive breast carcinomas in
postmenopausal women.
We found that both EB1089 and 1α,25-dihydroxyvitamin D3 were
able to inhibit aromatase-dependent cell growth in all three studied
EB1089 concentrations, showing that as low concentration of EB1089
as 10 nM was able to decrease aromatase-dependent cell growth
with approximately 50% (Fig. 1B). Thus, the EB1089-mediated down-
regulation of CYP19A1 gene expression (Fig. 1A) and the observed sig-
niﬁcant inhibition of testosterone-stimulated cell growth indicate that
EB1089 treatment result in reduced enzyme activity of aromatase.
3.3. EB1089 suppresses aromatase enzyme activity
The effect of EB1089 on the enzyme activity of aromatase was
assayed in breast cancer MCF-7 cells. Cells were seeded under standard
culture conditions and grown for 48 h. The cells were then treated with
10 or 100 nM EB1089 for 72 h. Following treatment, the medium was
changed to medium containing 10% NCS and the aromatase substrate
testosterone was added. Under these culture conditions, the aromatase
gene expression is stimulated and the cell growth is dependent on the
cells ability to convert testosterone to estrogens via aromatase,mimick-
ing the situation in estrogen-sensitive breast carcinomas in postmeno-
pausal women [29]. The conversion of testosterone to estradiol was
assayed during 48 h.
Treatment with EB1089 decreased the estradiol production signif-
icantly, from 30 pg/mL/48 h to 6–10 pg/mL/48 h (Fig. 1C) in MCF-7
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Fig. 1. (A) Effects of EB1089 treatment on mRNA level of CYP19A1 in breast cancer
MCF-7 cells. RNA was prepared from MCF-7 cells grown in standard growth medium
and treated with 10 nM or 100 nM EB1089 or with vehicle alone (ethanol) for 24 h.
Treatment with 100 nM 1α,25-dihydroxyvitamin D3 was used as a control. CYP19A1
mRNA expression level was determined using quantitative real-time RT-PCR. Error
bars represents the standard deviation (n=3–6). *Statistically signiﬁcant change in
aromatase mRNA level compared to EtOH (pb0.05). (B) Effects of EB1089 treatment
on aromatase-dependent cell growth. MCF-7 cells were cultured under conditions
where the cell proliferation could be stimulated by aromatase-catalyzed conversion
of testosterone to estradiol. Cells were seeded in medium with 1% FBS. Two days
after seeding, the medium was changed to medium with 10% NCS and testosterone
or vehicle alone (ethanol) was added. To the testosterone treated samples, EB1089
or 1α,25-dihydroxyvitamin D3 was added in the indicated concentrations to examine if
these substances were able to decrease the aromatase-dependent cell growth. Medium
was renewed every second or third day and cell numberwas assayed on day 6 using a col-
orimetric assay. Data are presented relative to the ethanol treated samples. Error bars rep-
resent standard deviation (n=4–6). *Statistically signiﬁcant difference compared to the
testosterone treated sample (pb0.05). (C) Effects of EB1089 on aromatase enzyme activ-
ity. MCF-7 cells were cultured in standard growth medium for 48 h. The cells were then
treated with EB1089 for 72 h. Following this pretreatment, the medium was changed to
medium containing 10% NCS and the aromatase substrate testosterone was added to
the cell culture for 48 h. The enzyme activity was then assayed bymeasuring the produc-
tion of estradiol during the incubation, using ELISA as described inMaterials andmethods.
Data are presented as enzyme activity (estradiol production pg/mL/48 h). Error bars
represent standard deviation (n=6). *Statistically signiﬁcant difference compared to
the control (pb0.05).
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gene expression also decreases the enzyme activity of aromatase
signiﬁcantly.3.4. Combined treatment with EB1089 and aromatase inhibitors
suppresses cell growth superior to single agent treatment
Clinically used aromatase inhibitors such as exemestane, anas-
trozole and letrozole act by blocking the enzyme activity. Treatment
with these aromatase inhibitors is associated with adverse effects due
to the effect on aromatase in other tissues than breast. The hormonally
active formof vitamin D has been reported to inhibit gene expression of
aromatase in breast cancer cells, but not in cells derived from other
tissues.
Therefore, we have investigated if a combined treatment with
EB1089 and low doses of the clinically used aromatase inhibitors
exemestane, anastrazole or letrozole could be a successful strategy to
strongly inhibit the aromatase-dependent cell growth. Fig. 2A shows
that the aromatase inhibitors exerted a dose-dependent growth in-
hibition and total suppression of aromatase-dependent growth stimu-
lation was observed with 100 nM (exemestane and letrozole) or 1 μM
(anastrozole). Treatment with 10 nM aromatase inhibitor resulted in
signiﬁcant, but not complete, blockade of aromatase-dependent cell
growth. Combined treatment with 100 nM EB1089 and 10 nM aroma-
tase inhibitor resulted in a strong decrease of aromatase-dependent
growth (Fig. 2B), with a signiﬁcantly lower cell growth than the
samples treated with EB1089 or aromatase inhibitor alone. Combined
treatment of 1α,25-dihydroxyvitamin D3 and clinically used aromatase
inhibitors was able to completely inhibit the aromatase-dependent cell
growth.
These results show that a combination of substances that inhibits
aromatase at both the gene expression level and by interacting with
the aromatase enzyme activity could be a successful strategy to inhibit
estrogen-responsive breast cancer cell growth using only low concen-
trations of aromatase inhibitors.3.5. Vitamin D analog EB1089 dissociates comodulator WSTF from the
CYP19A1 promoter in a VDR dependent manner
Breast cancer MCF-7 cells were cultured and treatedwith EB1089 to
study the molecular mechanism of the effect on CYP19A1 gene expres-
sion. Two negative vitamin D response elements (nVDRE) have been
proposed in the CYP19A1 promoter [9] and we studied if treatment
with EB1089 affected the recruitment of the vitamin D receptor (VDR)
to either of these putative nVDREs. Furthermore, we investigated if
comodulators VDIR and WSTF were involved in the mechanism by
which EB1089 downregulates the gene expression of CYP19A1. These
comodulators have previously been reported to be involved in vitamin
D-mediated regulation of the expression of other genes [30–32].
MCF-7 cells were cultured and treated with EB1089 or vehicle alone
(ethanol) for 24 h. The samples were then subjected to chromatin im-
munoprecipitation as described in Materials and methods. We found
that the VDR, VDIR and WSTF were associated with both the distal
and the proximal negative VDRE under standard culture conditions
and that treatment with EB1089 enhanced the recruitment of VDR to
the distal nVDRE in the CYP19A1 promoter (Fig. 3). The vitamin D
interacting protein VDIR, previously described to be involved in vitamin
D-induced repression of gene expression, was found to bind to the re-
sponse elements and EB1089 had no effect on VDIR binding. However,
treatment with EB1089 results in dissociation of the comodulator
WSTF from the distal nVDRE (Fig. 3A). In order to investigate the time
course of this interaction between comodulators and the distal
nVDRE, we also performed the chromatin immunoprecipitation de-
scribed above but with signiﬁcantly shorter treatment time. When
MCF-7 cells were treated with EB1089 for 1 h, only small and non-
signiﬁcant changes in the comodulator–promoter interaction were
detected at the distal nVDRE (Table 1A). Positive, negative and input
controls were analyzed in accordance with the manufacturer's recom-
mendations (Fig. 3B and Table 1B).
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Fig. 2. Treatment with EB1089 and aromatase inhibitors. MCF-7 cells were cultured under conditions where the cell proliferation could be stimulated by aromatase-catalyzed con-
version of testosterone to estradiol. Cells were seeded in medium with 1% FBS. Two days after seeding, the medium was changed to medium with 10% NCS and testosterone or
vehicle alone (ethanol) was added. (A) Dose–response study for the clinically used aromatase inhibitors letrozole, anastrozole and exemestane. (B) Combined treatment with
EB1089 or 1α,25-dihydroxyvitamin D3 and a low dose of a clinically used aromatase inhibitor (letrozole, anastrozole or exemestane). Medium was renewed every second or
third day and cell number was assayed on day 6 using a colorimetric assay. Data are presented relative to the ethanol treated samples. Error bars represent standard deviation
(n=4–6). *Statistically signiﬁcant difference compared to the vehicle control (B) or the testosterone treated samples (A) (pb0.05), °statistically signiﬁcant difference compared
to the corresponding sample treated with aromatase inhibitor alone (pb0.05).
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of Re-ChIP. MCF-7 cells treated with ethanol (control) or EB1089
were cross-linked and subjected to sequential immunoprecipitation
as described in Materials and methods. To study the effects of
EB1089 treatment on the binding of comodulators and receptors to
DNA sequences that interacts with VDIR, all samples were initially
immunoprecipitated with an antibody against VDIR. The samples
were then subjected to a second immunoprecipitation using anti-
bodies directed towards VDR or WSTF. The collected DNA was used
in real-time PCR with primers directed towards the distal nVDRE,
since the binding was most pronounced to this nVDRE. This assay
conﬁrms our ﬁndings from the ChIP assay, showing that treatment
with EB1089 recruits VDR to the distal nVDRE and dissociates WSTF
(Table 2).
We conclude that treatment with EB1089 leads to an altered bind-
ing of nuclear receptors/comodulators to the CYP19A1 promoter,
where VDR is recruited to the promoter while WSTF is dissociated.
3.6. Silencing of WSTF decreases CYP19A1 gene expression and
aromatase activity
Based on our ﬁnding that EB1089 treatment results in dissociation of
WSTF from the CYP19A1 promoter and that the gene expression of
CYP19A1 and activity of aromatase decreases at the same time, we hy-
pothesized thatWSTF could be an activator of the CYP19A1 gene expres-
sion. To test this hypothesis, we measured the CYP19A1mRNA levels in
MCF-7 cells transfected with siRNA directed towards WSTF and com-
pared it with themRNA level in MCF-7 cells transfected with scrambledsiRNA. We found (Fig. 4B) that cells with silenced expression of WSTF
had signiﬁcantly decreased levels of CYP19A1 mRNA compared to cells
transfectedwith scrambled siRNA. Furthermore, wemeasured the effect
ofWSTF silencing on the aromatase-dependent cell growth (cell culture
model described in Section 2.5) [29]. In this cell culture model, we used
MCF-7 cells transfected with siRNA directed towards WSTF and com-
pared the cell growth with MCF-7 cells transfected with scrambled
siRNA.We found that the aromatase-dependent cell growthwas signif-
icantly decreased in the samples that were transfected with siRNA for
WSTF comparedwith the samples thatwere transfectedwith scrambled
siRNA (control) (Fig. 4C). These results support our hypothesis that
WSTF might act as an activator of CYP19A1 gene expression.
4. Discussion
This paper reports that the vitamin D analog EB1089 can inhibit
the gene expression of aromatase in breast cancer cells, via a VDR/
WSTF mediated mechanism. Furthermore, we report that this effect
of EB1089 leads to decreased enzyme activity of aromatase and de-
creased cell growth of breast cancer cells.
The regulation of aromatase via interaction between the CYP19A1
promoter and comodulators WSTF and VDIR is a novel mechanism in
the regulation of aromatase and has not been reported previously. Our
experiments with siRNA knock-down of WSTF in MCF-7 cell showed
that the gene expression of CYP19A1 and the aromatase-dependent
cell growth was signiﬁcantly decreased in cells transfected with siRNA
againstWSTF comparedwith scrambled siRNA. Based on these ﬁndings,
and the ﬁndings that dissociation of WSTF from the CYP19A1 promoter
0
1
2
3
4
5
6
7
8
9
10
VDR VDIR WSTF VDR VDIR WSTF
Am
o
u
n
t D
N
A
(fo
ld
 
ch
an
ge
 
vs
 
VD
R 
Et
O
H)
Immunoprecipitating antibody
Control
EB1089
Distal nVDRE Proximal nVDRE
*
*
Input Positive
control 
Negative
control Input
Positive
control 
Negative
control 
Fold change 1,0 10,3 0,18 1,0 103,0 3,0
0
20
40
60
80
100
120
140
Am
o
u
n
t D
N
A
(fo
ld
 ch
an
ge
 
vs
 
in
pu
t)
Control EB1089
A
B
Fig. 3. Analysis of interaction of VDR, WSTF and VDIR with the CYP19A1 promoter.
(A) MCF-7 cells were cross-linked with formaldehyde and chromatin immunoprecipi-
tation was performed with antibodies against VDR, VDIR and WSTF. Recruitment of
VDR, VDIR and WSTF to the CYP19A1 promoter was analyzed by quantitative real-
time PCR with primers for the two putative VDREs. Data are presented relative to the
DNA amount in the sample treated with ethanol and immunoprecipitated with a
VDR antibody±standard deviation (n=3). *Statistically signiﬁcant difference com-
pared to the control (pb0.05). (B) Input control, positive control and negative control
were analyzed in accordance with the manufacturer's recommendations.
45J. Lundqvist et al. / Biochimica et Biophysica Acta 1833 (2013) 40–47by EB1089 decreases aromatase gene expression and enzyme activity,
we hypothesize that WSTF might act as an activator of CYP19A1 gene
expression. We suggest that WSTF is a very interesting drug target for
further research in the ﬁeld of breast cancer, since it could be a new
strategy to decrease aromatase activity in breast cancer cells.
The mechanism for vitamin D-mediated suppression of gene ex-
pression in general remains unclear [33] and it has recently been
reported that VDR can bind both to promoter regions and withinTable 1
Analysis of interaction of VDR, WSTF and VDIR with the CYP19A1 promoter. MCF-7 cells
were treated with EB1089 for 1 h and were then cross-linked with formaldehyde and
chromatin immunoprecipitation was performedwith antibodies against VDR, VDIR and
WSTF. (A) Recruitment of VDR, VDIR and WSTF to the CYP19 promoter was analyzed
by quantitative real-time PCR with primers for the distal putative VDREs. Data are
presented relative to the DNA amount in the sample treated with ethanol±standard
deviation (n=3). (B) Input control, positive control and negative control were ana-
lyzed in accordance with the manufacturer's recommendations. n.d., non-detectable.
Table 1A
Immunoprecipitating
antibody
Fold change vs. control p-value
Control EB1089 (Control vs. EB1089)
VDR 1 0.72 (±0.21) 0.35
VDIR 1 0.61 (±0.31) 0.12
WSTF 1 0.83 (±0.20) 0.61
Table 1B
Immunoprecipitating
antibody
Fold change vs. input
Control EB1089
Input 1 (±0.14) 1 (±0.02)
Positive control 3.8 (±0.52) 2.8 (±0.46)
Negative control 0.47 (±0.02) n.d.gene introns and exons [34,35] and thereby alter the gene expression.
It has been shown for the CYP27B1 gene and the parathyroid hormone
gene that the VDR interacting repressor (VDIR) and the Williams syn-
drome transcription factor (WSTF) act as key comodulators of VDR
activity [31,32,36,37]. However, the previous studies suggest that
WSTF act as a repressor of CYP27B1 gene expression, while it in our
studies acts as an activator of CYP19A1 gene expression. The mecha-
nism for vitamin D-induced gene regulation reported in this paper,
recruitment of VDR and simultaneous dissociation of WSTF, was de-
scribed for the ﬁrst time very recently when Lundqvist et al. [30]
reported that the promoter activity and gene expression of CYP21A2
is regulated via this mechanism. This study provides new knowledge
in the research of mechanisms for vitamin D-mediated repression of
gene expression. However, further research is needed to elucidate
the detailed mechanism for vitamin D-mediated downregulation of
gene expression and the comodulators involved. The new and in-
triguing ChIP-seq data showing that vitamin D response elements
may be located both in the promoter sequence of a gene and within
the introns or exons [34,35,38–42] prompt further investigation on
the mechanism by which vitamin D and vitamin D analogs regulate
gene expression. Our data does not exclude the possibility that EB1089
or 1α,25-dihydroxyvitamin D3 may also bind to other sites within the
CYP19A1 promoter or gene.
In order to ﬁnd substances with retained anti-proliferative effects,
but with less pronounced hypercalcemic effect than 1α,25-
dihydroxyvitamin D3, a large number of vitamin D analogs have
been synthesized [43]. EB1089 is one of those vitamin D analogs
that have been extensively used in the investigations of anti-cancer
effects. EB1089 has been reported to exert multiple anti-cancer
effects in vitro, including decreased cell proliferation, increased cell
differentiation, down-regulation of estrogen receptor α, down-
regulation of Bcl-2 and triggering of lysosomal changes [16,44–47].
In vivo, it has been shown that EB1089 is able to inhibit the progres-
sion of mammary tumors and the metastasis formation and increase
the survival time [17–24] in different animal models. The ﬁnding
reported in this paper that EB1089 can inhibit aromatase in breast
cancer cells adds a new anti-breast cancer effect to the previously
reported in vitro and in vivo effects of EB1089. This emphasizes that
EB1089 is an interesting anti-cancer substance for further research,
especially in the ﬁeld of breast cancer. Based on our ﬁndings and
the fact that EB1089 previously has been reported not to alter the en-
zyme activity of aromatase in ovarian cells [48], we hypothesize that
EB1089 functions as a tissue-selective aromatase modulator, where
the effect of EB1089 differs between tissues.
In clinical trials, EB1089 has been tested against advanced forms of
hepatocellular, pancreatic and colorectal cancers with mixed results.
In the study by Dalhoff et al. [25], EB1089 was found to have a reduc-
ing effect on tumor dimensions in some of the patients with inopera-
ble hepatocellular carcinoma. Two patients had complete response
following EB1089 treatment. In the clinical trial including patients
with inoperable pancreatic cancer, no objective response was ob-
served [26]. However, very little clinical data are available regarding
breast cancer and EB1089. EB1089 has been used in only one clinical
trial with breast cancer patients [27]. This was a very small study with
only 25 breast cancer patients, all with advanced carcinomas. All
breast cancer patients in the study had received anti-cancer therapy
previously; many of the patients had underwent more than three dif-
ferent anti-cancer treatments before they were included in this clini-
cal trial. Based on the ﬁndings presented in this study that EB1089
downregulates CYP19A1 gene expression and aromatase activity, it
is our opinion that clinical trials with EB1089 should be performed
with patients with early stages of estrogen-sensitive breast carcinomas
rather than with patients with heavily treated advanced carcinomas,
since more advanced breast carcinomas tend to grow in an estrogen-
independent manner. Based on our ﬁndings, we suggest that further
research should be directed to study the effects of EB1089 on
Table 2
Analysis of interaction of VDR and WSTF to binding sites for VDIR in the CYP19 promoter. MCF-7 cells grown in standard growth medium were treated with either EB1089 or eth-
anol (control) for 24 h. Cell lysates were subjected to sequential chromatin immunoprecipitation as described in Materials and methods. All samples were ﬁrst subjected to immu-
noprecipitation using the antibody against VDIR. The samples were then subjected to immunoprecipitation using antibodies against either VDR or WSTF. Following chromatin
immunoprecipitation, the amount of DNA in each sample was measured using real-time PCR with primers directed towards the distal nVDRE. The results are presented as fold
change compared to the amount of DNA (distal nVDRE) in ethanol treated samples subjected to the same immunoprecipitation. Data are presented relative to the DNA amount
in the sample treated with ethanol±standard deviation (n=3).
Antibody ﬁrst
immunoprecipitation
Antibody second
immunoprecipitation
Fold change vs. control p-value
Control EB1089 (Control vs. EB1089)
VDIR VDR 1 21.4 (±12.5) b0.05
VDIR WSTF 1 0.03 (±0.04) b0.001
46 J. Lundqvist et al. / Biochimica et Biophysica Acta 1833 (2013) 40–47estrogen-sensitive breast cancers in vivo. The clinical trials with EB1089
that has been published [25–27] have all used patients with different
forms of advanced carcinomas. Our data indicate that EB1089 could be
more effective if it was tested on earlier stages of breast cancer. ThisA
*
0
20
40
60
80
100
120
siControl siWSTF
m
R
NA
 
le
ve
l C
YP
19
A1
(%
 
of
 
co
nt
ro
l)
B
*
0.0
0.5
1.0
1.5
2.0
2.5
3.0
EtOH Testosterone EtOH Testosterone
Ar
om
a
ta
se
 d
e
pe
nd
e
nt
 c
e
ll 
gr
ow
th
-
fo
ld
 c
ha
ng
e
 
ve
rs
us
 
co
nt
ro
l
siControl siWSTFC
Fig. 4. Role for comodulatorWSTF in CYP19A1 gene expression and aromatase-dependent
cell growth. (A) The effect of siRNA transfection on WSTF protein level in MCF-7 cells
determined by Western blot analysis. (B) MCF-7 cells were treated with scrambled
siRNA or WSTF speciﬁc siRNA and cultured in medium with 10% NCS with testosterone
for 4 days. CYP19A1 mRNA level was measured using real-time RT-PCR and cells
transfected with scrambled siRNA were compared with cells transfected with WSTF
speciﬁc siRNA (n=3). *Statistically signiﬁcant difference compared to the scrambled
siRNA control (pb0.05). (C) MCF-7 cells were treated with scrambled siRNA or WSTF
speciﬁc siRNA and cultured in medium with 10% NCS with and without testosterone for
5 days. Cell growth was determined by a colorimetric assay. Data are presented as fold
change compared to the control group±standard deviation (n=6). *Statistically signiﬁ-
cant difference compared to the scrambled siRNA control (pb0.05).reinforces the interest of EB1089, and other vitamin D analogs, as inter-
esting anti-cancer agents for further research.
Our results show that a combination of EB1089 and a low dose of
clinically used aromatase inhibitors can be used to strongly inhibit the
aromatase-dependent cell growth by acting via different mechanism;
EB1089 decreases aromatase gene expression and the aromatase in-
hibitors inhibit the enzyme activity via a direct interaction with the
protein. Such treatment could beneﬁt patients by giving rise to fewer
adverse effects than treatment with high doses of aromatase inhibitors
such as exemestane, anastrazole or letrozole alone. Furthermore, based
on this study and previous publications on tissue-selective effects of
1α,25-dihydroxyvitamin D3 [8,9] it can by hypothesized that the
down regulatory effects of EB1089 on CYP19A1 gene expression would
be limited to carcinogenic breast tissue, due to the tissue-selective use
of CYP19A1 promoters. We suggest that combined treatment of aroma-
tase inhibitors and vitamin D analogs should be subject for further eval-
uation of a beneﬁcial effect for breast cancer patients.
In conclusion, this paper reports a new regulatory pathway for
aromatase gene expression and a novel mechanism for vitamin D re-
ceptor mediated effects on gene expression in general. We conclude
that it is of high priority to further evaluate the role of WSTF as a po-
tential future drug target in breast cancer treatment and to test com-
bined treatment with aromatase inhibitors and vitamin D analogs.
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